A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the difference in learning and performance measures associated with repeated use of an iPad video game (Akili Interactive's Project: EVO) in healthy elderly volunteers based on amyloid status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494

Early Alzheimer's Disease

RECRUITING PHASE2

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

NCT06597058

Alzheimer Disease

ACTIVE_NOT_RECRUITING PHASE2

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

NCT05466422

Alzheimer Disease

COMPLETED PHASE1

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046

Alzheimer's Disease

COMPLETED PHASE2

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

NCT06546995

Alzheimer's Disease Healthy Elderly

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

(Amyloid Negative)

Ritalin

Intervention Type DRUG

1 - 20 mg tablet taken once on Day 0 and taken once on Day 28

Placebo

Intervention Type DRUG

1 - matching tablet taken once on Day 0 and once on Day 28

Amyloid Positive

Ritalin

Intervention Type DRUG

1 - 20 mg tablet taken once on Day 0 and taken once on Day 28

Placebo

Intervention Type DRUG

1 - matching tablet taken once on Day 0 and once on Day 28

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ritalin

1 - 20 mg tablet taken once on Day 0 and taken once on Day 28

Intervention Type DRUG

Placebo

1 - matching tablet taken once on Day 0 and once on Day 28

Intervention Type DRUG

Ritalin

1 - 20 mg tablet taken once on Day 0 and taken once on Day 28

Intervention Type DRUG

Placebo

1 - matching tablet taken once on Day 0 and once on Day 28

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

methylphenidate hydrochloride 20mg tablet taken once on day 0 and once on day 28 matched placebo tablet taken once on day 0 and once on day 28 methylphenidate hydrochloride 20mg tablet taken once on day 0 and once on day 28 matched placebo tablet taken once on day 0 and once on day 28

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males and females between the ages of 70 and 80.
* Subjects must have BMI of 17.5 to 32 kg/m2 and total body weight \> 110 pounds.
* Acceptable screening MRI and PET scans that pass quality control requirements.

Exclusion Criteria

* Co-morbid diagnosis of clinically documented Alzheimer's disease; - Significant cognitive impairment;
* MMSE (mini mental state examination) score \<26

Minimum Eligible Age

70 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes